Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy

The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received p...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Kabsoo Shin [verfasserIn] Joori Kim [verfasserIn] Se Jun Park [verfasserIn] Hyunho Kim [verfasserIn] Myung Ah Lee [verfasserIn] Okran Kim [verfasserIn] Juyeon Park [verfasserIn] Nahyeon Kang [verfasserIn] In-Ho Kim [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	platinum-based chemotherapy advanced gastric cancer mononuclear cells fluorescence-activated cell sorting progression-free survival overall survival

Übergeordnetes Werk:	In: Cancers - MDPI AG, 2010, 15(2023), 15, p 3955
Übergeordnetes Werk:	volume:15 ; year:2023 ; number:15, p 3955

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/cancers15153955

Katalog-ID:	DOAJ093716281

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ093716281
003	DE-627
005	20240413015430.0
007	cr uuu---uuuuu
008	240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/cancers15153955 \|2 doi
035			\|a (DE-627)DOAJ093716281
035			\|a (DE-599)DOAJa57f00ae0677463989e3607d0d1d1044
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Kabsoo Shin \|e verfasserin \|4 aut
245	1	0	\|a Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell groups. The increased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group (PFS: 8.7 months vs. 6.1 months, <i<p</i< = 0.007; OS: 20.7 months vs. 10.8 months, <i<p</i< = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, <i<p</i< = 0.041). Multivariate analysis revealed that an increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy.
650		4	\|a platinum-based chemotherapy
650		4	\|a advanced gastric cancer
650		4	\|a mononuclear cells
650		4	\|a fluorescence-activated cell sorting
650		4	\|a progression-free survival
650		4	\|a overall survival
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Joori Kim \|e verfasserin \|4 aut
700	0		\|a Se Jun Park \|e verfasserin \|4 aut
700	0		\|a Hyunho Kim \|e verfasserin \|4 aut
700	0		\|a Myung Ah Lee \|e verfasserin \|4 aut
700	0		\|a Okran Kim \|e verfasserin \|4 aut
700	0		\|a Juyeon Park \|e verfasserin \|4 aut
700	0		\|a Nahyeon Kang \|e verfasserin \|4 aut
700	0		\|a In-Ho Kim \|e verfasserin \|4 aut
773	0	8	\|i In \|t Cancers \|d MDPI AG, 2010 \|g 15(2023), 15, p 3955 \|w (DE-627)614095670 \|w (DE-600)2527080-1 \|x 20726694 \|7 nnns
773	1	8	\|g volume:15 \|g year:2023 \|g number:15, p 3955
856	4	0	\|u https://doi.org/10.3390/cancers15153955 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/a57f00ae0677463989e3607d0d1d1044 \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2072-6694/15/15/3955 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2072-6694 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 15 \|j 2023 \|e 15, p 3955

Indexfelder

author_variant	k s ks j k jk s j p sjp h k hk m a l mal o k ok j p jp n k nk i h k ihk
matchkey_str	article:20726694:2023----::alicesicruaigdspuc8uspclsrdcsaoalsriaiptetwtavne
hierarchy_sort_str	2023
callnumber-subject-code	RC
publishDate	2023
allfields	10.3390/cancers15153955 doi (DE-627)DOAJ093716281 (DE-599)DOAJa57f00ae0677463989e3607d0d1d1044 DE-627 ger DE-627 rakwb eng RC254-282 Kabsoo Shin verfasserin aut Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell groups. The increased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group (PFS: 8.7 months vs. 6.1 months, <i<p</i< = 0.007; OS: 20.7 months vs. 10.8 months, <i<p</i< = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, <i<p</i< = 0.041). Multivariate analysis revealed that an increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy. platinum-based chemotherapy advanced gastric cancer mononuclear cells fluorescence-activated cell sorting progression-free survival overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens Joori Kim verfasserin aut Se Jun Park verfasserin aut Hyunho Kim verfasserin aut Myung Ah Lee verfasserin aut Okran Kim verfasserin aut Juyeon Park verfasserin aut Nahyeon Kang verfasserin aut In-Ho Kim verfasserin aut In Cancers MDPI AG, 2010 15(2023), 15, p 3955 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:15, p 3955 https://doi.org/10.3390/cancers15153955 kostenfrei https://doaj.org/article/a57f00ae0677463989e3607d0d1d1044 kostenfrei https://www.mdpi.com/2072-6694/15/15/3955 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 15, p 3955
spelling	10.3390/cancers15153955 doi (DE-627)DOAJ093716281 (DE-599)DOAJa57f00ae0677463989e3607d0d1d1044 DE-627 ger DE-627 rakwb eng RC254-282 Kabsoo Shin verfasserin aut Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell groups. The increased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group (PFS: 8.7 months vs. 6.1 months, <i<p</i< = 0.007; OS: 20.7 months vs. 10.8 months, <i<p</i< = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, <i<p</i< = 0.041). Multivariate analysis revealed that an increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy. platinum-based chemotherapy advanced gastric cancer mononuclear cells fluorescence-activated cell sorting progression-free survival overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens Joori Kim verfasserin aut Se Jun Park verfasserin aut Hyunho Kim verfasserin aut Myung Ah Lee verfasserin aut Okran Kim verfasserin aut Juyeon Park verfasserin aut Nahyeon Kang verfasserin aut In-Ho Kim verfasserin aut In Cancers MDPI AG, 2010 15(2023), 15, p 3955 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:15, p 3955 https://doi.org/10.3390/cancers15153955 kostenfrei https://doaj.org/article/a57f00ae0677463989e3607d0d1d1044 kostenfrei https://www.mdpi.com/2072-6694/15/15/3955 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 15, p 3955
allfields_unstemmed	10.3390/cancers15153955 doi (DE-627)DOAJ093716281 (DE-599)DOAJa57f00ae0677463989e3607d0d1d1044 DE-627 ger DE-627 rakwb eng RC254-282 Kabsoo Shin verfasserin aut Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell groups. The increased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group (PFS: 8.7 months vs. 6.1 months, <i<p</i< = 0.007; OS: 20.7 months vs. 10.8 months, <i<p</i< = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, <i<p</i< = 0.041). Multivariate analysis revealed that an increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy. platinum-based chemotherapy advanced gastric cancer mononuclear cells fluorescence-activated cell sorting progression-free survival overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens Joori Kim verfasserin aut Se Jun Park verfasserin aut Hyunho Kim verfasserin aut Myung Ah Lee verfasserin aut Okran Kim verfasserin aut Juyeon Park verfasserin aut Nahyeon Kang verfasserin aut In-Ho Kim verfasserin aut In Cancers MDPI AG, 2010 15(2023), 15, p 3955 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:15, p 3955 https://doi.org/10.3390/cancers15153955 kostenfrei https://doaj.org/article/a57f00ae0677463989e3607d0d1d1044 kostenfrei https://www.mdpi.com/2072-6694/15/15/3955 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 15, p 3955
allfieldsGer	10.3390/cancers15153955 doi (DE-627)DOAJ093716281 (DE-599)DOAJa57f00ae0677463989e3607d0d1d1044 DE-627 ger DE-627 rakwb eng RC254-282 Kabsoo Shin verfasserin aut Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell groups. The increased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group (PFS: 8.7 months vs. 6.1 months, <i<p</i< = 0.007; OS: 20.7 months vs. 10.8 months, <i<p</i< = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, <i<p</i< = 0.041). Multivariate analysis revealed that an increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy. platinum-based chemotherapy advanced gastric cancer mononuclear cells fluorescence-activated cell sorting progression-free survival overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens Joori Kim verfasserin aut Se Jun Park verfasserin aut Hyunho Kim verfasserin aut Myung Ah Lee verfasserin aut Okran Kim verfasserin aut Juyeon Park verfasserin aut Nahyeon Kang verfasserin aut In-Ho Kim verfasserin aut In Cancers MDPI AG, 2010 15(2023), 15, p 3955 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:15, p 3955 https://doi.org/10.3390/cancers15153955 kostenfrei https://doaj.org/article/a57f00ae0677463989e3607d0d1d1044 kostenfrei https://www.mdpi.com/2072-6694/15/15/3955 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 15, p 3955
allfieldsSound	10.3390/cancers15153955 doi (DE-627)DOAJ093716281 (DE-599)DOAJa57f00ae0677463989e3607d0d1d1044 DE-627 ger DE-627 rakwb eng RC254-282 Kabsoo Shin verfasserin aut Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell groups. The increased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group (PFS: 8.7 months vs. 6.1 months, <i<p</i< = 0.007; OS: 20.7 months vs. 10.8 months, <i<p</i< = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, <i<p</i< = 0.041). Multivariate analysis revealed that an increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy. platinum-based chemotherapy advanced gastric cancer mononuclear cells fluorescence-activated cell sorting progression-free survival overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens Joori Kim verfasserin aut Se Jun Park verfasserin aut Hyunho Kim verfasserin aut Myung Ah Lee verfasserin aut Okran Kim verfasserin aut Juyeon Park verfasserin aut Nahyeon Kang verfasserin aut In-Ho Kim verfasserin aut In Cancers MDPI AG, 2010 15(2023), 15, p 3955 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:15 year:2023 number:15, p 3955 https://doi.org/10.3390/cancers15153955 kostenfrei https://doaj.org/article/a57f00ae0677463989e3607d0d1d1044 kostenfrei https://www.mdpi.com/2072-6694/15/15/3955 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 15 2023 15, p 3955
language	English
source	In Cancers 15(2023), 15, p 3955 volume:15 year:2023 number:15, p 3955
sourceStr	In Cancers 15(2023), 15, p 3955 volume:15 year:2023 number:15, p 3955
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	platinum-based chemotherapy advanced gastric cancer mononuclear cells fluorescence-activated cell sorting progression-free survival overall survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Cancers
authorswithroles_txt_mv	Kabsoo Shin @@aut@@ Joori Kim @@aut@@ Se Jun Park @@aut@@ Hyunho Kim @@aut@@ Myung Ah Lee @@aut@@ Okran Kim @@aut@@ Juyeon Park @@aut@@ Nahyeon Kang @@aut@@ In-Ho Kim @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	614095670
id	DOAJ093716281
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ093716281</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413015430.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers15153955</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ093716281</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa57f00ae0677463989e3607d0d1d1044</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Kabsoo Shin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell groups. The increased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group (PFS: 8.7 months vs. 6.1 months, <i<p</i< = 0.007; OS: 20.7 months vs. 10.8 months, <i<p</i< = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, <i<p</i< = 0.041). Multivariate analysis revealed that an increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">platinum-based chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">advanced gastric cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mononuclear cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fluorescence-activated cell sorting</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">progression-free survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">overall survival</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joori Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Se Jun Park</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hyunho Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Myung Ah Lee</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Okran Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Juyeon Park</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nahyeon Kang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">In-Ho Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">15(2023), 15, p 3955</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:15, p 3955</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers15153955</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a57f00ae0677463989e3607d0d1d1044</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/15/15/3955</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2023</subfield><subfield code="e">15, p 3955</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Kabsoo Shin
spellingShingle	Kabsoo Shin misc RC254-282 misc platinum-based chemotherapy misc advanced gastric cancer misc mononuclear cells misc fluorescence-activated cell sorting misc progression-free survival misc overall survival misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy
authorStr	Kabsoo Shin
ppnlink_with_tag_str_mv	@@773@@(DE-627)614095670
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	20726694
topic_title	RC254-282 Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy platinum-based chemotherapy advanced gastric cancer mononuclear cells fluorescence-activated cell sorting progression-free survival overall survival
topic	misc RC254-282 misc platinum-based chemotherapy misc advanced gastric cancer misc mononuclear cells misc fluorescence-activated cell sorting misc progression-free survival misc overall survival misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc platinum-based chemotherapy misc advanced gastric cancer misc mononuclear cells misc fluorescence-activated cell sorting misc progression-free survival misc overall survival misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc platinum-based chemotherapy misc advanced gastric cancer misc mononuclear cells misc fluorescence-activated cell sorting misc progression-free survival misc overall survival misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Cancers
hierarchy_parent_id	614095670
hierarchy_top_title	Cancers
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)614095670 (DE-600)2527080-1
title	Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy
ctrlnum	(DE-627)DOAJ093716281 (DE-599)DOAJa57f00ae0677463989e3607d0d1d1044
title_full	Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy
author_sort	Kabsoo Shin
journal	Cancers
journalStr	Cancers
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
author_browse	Kabsoo Shin Joori Kim Se Jun Park Hyunho Kim Myung Ah Lee Okran Kim Juyeon Park Nahyeon Kang In-Ho Kim
container_volume	15
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Kabsoo Shin
doi_str_mv	10.3390/cancers15153955
author2-role	verfasserin
title_sort	early increase in circulating pd-1<sup<+</sup<cd8<sup<+</sup< t cells predicts favorable survival in patients with advanced gastric cancer receiving chemotherapy
callnumber	RC254-282
title_auth	Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy
abstract	The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell groups. The increased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group (PFS: 8.7 months vs. 6.1 months, <i<p</i< = 0.007; OS: 20.7 months vs. 10.8 months, <i<p</i< = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, <i<p</i< = 0.041). Multivariate analysis revealed that an increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy.
abstractGer	The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell groups. The increased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group (PFS: 8.7 months vs. 6.1 months, <i<p</i< = 0.007; OS: 20.7 months vs. 10.8 months, <i<p</i< = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, <i<p</i< = 0.041). Multivariate analysis revealed that an increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy.
abstract_unstemmed	The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell groups. The increased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group (PFS: 8.7 months vs. 6.1 months, <i<p</i< = 0.007; OS: 20.7 months vs. 10.8 months, <i<p</i< = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, <i<p</i< = 0.041). Multivariate analysis revealed that an increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	15, p 3955
title_short	Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy
url	https://doi.org/10.3390/cancers15153955 https://doaj.org/article/a57f00ae0677463989e3607d0d1d1044 https://www.mdpi.com/2072-6694/15/15/3955 https://doaj.org/toc/2072-6694
remote_bool	true
author2	Joori Kim Se Jun Park Hyunho Kim Myung Ah Lee Okran Kim Juyeon Park Nahyeon Kang In-Ho Kim
author2Str	Joori Kim Se Jun Park Hyunho Kim Myung Ah Lee Okran Kim Juyeon Park Nahyeon Kang In-Ho Kim
ppnlink	614095670
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/cancers15153955
callnumber-a	RC254-282
up_date	2024-07-03T18:59:17.246Z
_version_	1803585487903916032
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ093716281</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413015430.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers15153955</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ093716281</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa57f00ae0677463989e3607d0d1d1044</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Kabsoo Shin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The clinical significance of PD-1 expression in circulating CD8<sup<+</sup< T cells in patients with gastric cancer (GC) receiving chemotherapy remains unelucidated. Therefore, we aimed to examine its prognostic significance in blood samples of 68 patients with advanced GC who received platinum-based chemotherapy. The correlation between peripheral blood mononuclear cells, measured using fluorescence-activated cell sorting, was evaluated. Patients were divided into two groups according to the changes in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequencies between day 0 and 7. They were categorized as increased or decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell groups. The increased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group showed longer progression-free survival (PFS) and overall survival (OS) than the decreased PD-1<sup<+</sup<CD8<sup<+</sup< T-cell group (PFS: 8.7 months vs. 6.1 months, <i<p</i< = 0.007; OS: 20.7 months vs. 10.8 months, <i<p</i< = 0.003). The mean duration of response was significantly different between the groups (5.7 months vs. 2.5 months, <i<p</i< = 0.041). Multivariate analysis revealed that an increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency was an independent prognostic factor. We concluded that the early increase in PD-1<sup<+</sup<CD8<sup<+</sup< T-cell frequency is a potential predictor of favorable prognoses and durable responses in patients with advanced GC receiving chemotherapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">platinum-based chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">advanced gastric cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mononuclear cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fluorescence-activated cell sorting</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">progression-free survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">overall survival</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joori Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Se Jun Park</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hyunho Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Myung Ah Lee</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Okran Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Juyeon Park</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nahyeon Kang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">In-Ho Kim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">15(2023), 15, p 3955</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:15, p 3955</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers15153955</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a57f00ae0677463989e3607d0d1d1044</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/15/15/3955</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2023</subfield><subfield code="e">15, p 3955</subfield></datafield></record></collection>
score	7.401127

Nicht das Richtige dabei?

Schreiben Sie uns!

Early Increase in Circulating PD-1<sup<+</sup<CD8<sup<+</sup< T Cells Predicts Favorable Survival in Patients with Advanced Gastric Cancer Receiving Chemotherapy

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?